← All diseases
Liver, kidneys and digestion
Fatty liver disease (MASH/NASH), advanced
Do you want to receive a message when there is new research about Liver Fat (MASH/NASH), advanced? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a single sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research on Liver Steatosis (MASH/NASH), Advanced is available. View what Premium costs.
Publications and studies (2550)
- Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway. (2024/08/14) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds. (2024/08/08) ♡
- Xiezhuo Tiaozhi formula inhibits macrophage pyroptosis in the non-alcoholic fatty liver disease by targeting the SIRT1 pathway. (2024/08/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Effect of Modified Xiaoyao Powder on intestinal barrier and intestinal flora in mice with metabolic associated fatty liver disease based on "gut-liver axis"]. (2024/08/01) ♡
- Shenling Baizhu powder alleviates non-alcoholic fatty liver disease by modulating autophagy and energy metabolism in high-fat diet-induced rats. (2024/07/25) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial. (2024/07/25) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Regulatory effect of Diwu Yanggan Decoction on lysoglycerophospholipids in circulating exosomes in a mouse model of nonalcoholic fatty liver disease]. (2024/07/20) ♡
- An herbal formulation "Shugan Xiaozhi decoction" ameliorates methionine/choline deficiency-induced nonalcoholic steatohepatitis through regulating inflammation and apoptosis-related pathways. (2024/07/15) ♡
- Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways. (2024/07/15) ♡
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease. (2024/07/15) ♡
- Licochalcone D ameliorates lipid metabolism in hepatocytes by modulating lipogenesis and autophagy. (2024/07/15) ♡
- Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis. (2024/07/14) ♡
- Wulingsan Alleviates MAFLD by Activating Autophagy via Regulating the AMPK/mTOR/ULK1 Signaling Pathway. (2024/07/13) ♡
- Assessing the health and economic burden of obesity-related complications in East-Asian populations: implementation of risk equations in the Core Obesity Model for Japan and model validation. (2024/07/12) ♡
- The molecular and network mechanisms of antilipidemic potential effects of Ganfule capsules in nonalcoholic fatty liver disease. (2024/07/10) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Potential therapeutic strategies for MASH: from preclinical to clinical development. (2024/07/06) ♡
- A Mendelian randomization study: Years of education and nonalcoholic fatty liver disease. (2024/07/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications. (2024/07/05) ♡
- Associations of activity, sedentary and sleep behaviors with prevalent steatotic liver disease in middle-aged and older adults: the ELSA-Brasil study. (2024/07/03) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease. (2024/07/03) ♡
- Mechanism of Xiaoyao San in treating non-alcoholic fatty liver disease with liver depression and spleen deficiency: based on bioinformatics, metabolomics and in vivo experiments. (2024/07/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations. (2024/07/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. From NAFLD to MASLD: Promise and pitfalls of a new definition. (2024/07/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease. (2024/07/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition". (2024/07/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. From NAFLD to MASLD: Promise and pitfalls of a new definition. (2024/07/01) ♡
- Compound Shouwu Jiangzhi Granule regulates triacylglyceride synthesis to alleviate hepatic lipid accumulation. (2024/07/01) ♡
- Protocatechuic Acid Protects Mice Against Non-Alcoholic Fatty Liver Disease by Attenuating Oxidative Stress and Improving Lipid Profile. (2024/07/01) ♡
- Multiparametric Liver Biomarker Analysis Using MR Elastography and MRI for Non-Invasive Assessment of Fibrosis, Steatosis, and Iron Overload in Patients with Non-Alcoholic Fatty Liver Disease. (2024/07/01) ♡
- Predicting Nonalcoholic Fatty Liver Disease in Obese Populations with 3D Body Scans. (2024/07/01) ♡
- Si-Wu-Tang attenuates hepatocyte PANoptosis and M1 polarization of macrophages in non-alcoholic fatty liver disease by influencing the intercellular transfer of mtDNA. (2024/06/28) ♡
- Dramatic Suppression of Lipogenesis and No Increase in Beta-Oxidation Gene Expression Are among the Key Effects of Bergamot Flavonoids in Fatty Liver Disease. (2024/06/25) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Exploring the therapeutic potential of silymarin-based herbal remedy (prebiotic) and probiotic blend in a mouse model of NAFLD: Insights into gut microbiota modulation and liver health. (2024/06/22) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. A gut microbiota-independent mechanism shapes the bile acid pool in mice with MASH. (2024/06/20) ♡
- Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy. (2024/06/18) ♡
- Diabetes Complications among Inpatients with Childhood and Young Adult-Onset Type 1 and 2 Diabetes. (2024/06/14) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Gynostemma pentaphyllum Extract Alleviates NASH in Mice: Exploration of Inflammation and Gut Microbiota. (2024/06/06) ♡
- Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota. (2024/06/04) ♡
- The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse. (2024/06/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A promising therapy for fatty liver disease: PCSK9 inhibitors. (2024/06/01) ♡
- Exploring novel indazole derivatives as ASK1 inhibitors: Design, synthesis, biological evaluation and docking studies. (2024/06/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis. (2024/06/01) ♡
- Spatial multi-omics characterizes GPR35-relevant lipid metabolism signatures across liver zonation in MASLD. (2024/05/31) ♡
- Non-alcoholic fatty liver disease related knowledge among a sample of Egyptians: an exploratory cross-sectional study. (2024/05/30) ♡
- Chaihu Guizhi Ganjiang Decoction attenuates nonalcoholic steatohepatitis by enhancing intestinal barrier integrity and ameliorating PPARα mediated lipotoxicity. (2024/05/23) ♡
- Indigenous wisdom of a Kwatha to treat NASH: An insight into the mechanism. (2024/05/23) ♡
- IRF8 aggravates nonalcoholic fatty liver disease via BMAL1/PPARγ axis. (2024/05/20) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Regulation of electroacupuncture on non-canonical pathway of hepatocellular pyroptosis in rats with nonalcoholic fatty liver disease]. (2024/05/12) ♡
- Integrated network pharmacology, metabolomics, and transcriptomics of Huanglian-Hongqu herb pair in non-alcoholic fatty liver disease. (2024/05/10) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Pogostone attenuated high-fat diet-induced nonalcoholic fatty liver disease in mice through inhibition of NLRP3 inflammasome signaling. (2024/05/05) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.